Dyslipidemia and Type 2 Diabetes Flashcards
indications of PCSK9 inhibitors
Indicated when more LDL-C lowering is needed despite maximally “tolerated” statin therapy:
- Heterozygous Familial Hypercholesterolemia (FH)
- Homozygous FH – Evolocumab only
- Patients with known ASCVD (high risk patients
characteristic of plaque prone to rupture
-fibrous cap over lipid core (thin wall- prone to rupture)
how do the current guidelines use HDL
use HDL primarily as a risk marker and use statins as indicated
NCEP ATP III steps in management of dyslipidemia
evaluate
Set goals
Treat and educate
caveats to measuring lipoprotein profile
- Biologic variation 4-12%
- Seasonal variability 10% higher winter
- Lab variability 5 – 7%
**Therefore, repeated measurements are recommended
risk factors used in ASCVD calculation
- Sex – Age – Race (White, African American, other) – Total Cholesterol (untreated) – HDL – Systolic BP (current) – Treatment for HTN (Y/N) – Diabetes (Y/N) – Smoker (Y/N)
*theres an APP for this
if one experiences true myopathy with a statin what should you do
stop the statin and retry them on another one
biological roles of HDL
- HDL “removes” cholesterol from periphery?
- HDL has antioxidant and anti-inflammatory effects
Low HDL levels are associated with ____
High HDL levels are associated with ____
increased risk for CVD
a protective effect against CVD
*Unclear whether HDL raising reduces CVD related events/death
Cholesterol lowering therapy especially with statin therapy is effective in preventing __
acute atherosclerotic events, both acutely and chronically
Heterozygous Familial Hypobetalipoproteinemia is associated with
LDL-C of ~20-30 and longevity
Calculate LDL using Friedewald formula:
In fasted state (TG less than 400): LDL = Total-C – HDL – TG/5 + VLDL
traditional Major CVD risk factors
- Cigarette smoking
- Hypertension
- Low HDL-C: less than 40 mg/dL*
- Family history of premature CHD (1st-degree): male relative age less than 55 years and female relative age less than 65 years
- Age (male less/equal to 45 years, female less/equal to 55 years)
*HDL-C greater/equal to 60 mg/dL is a negative risk factor.
benefits of statins
- help reduce dementia
- plaque regression
- decrease circulating LDL
- stabilize plaque
describe endogenous lipid metabolism
Liver secretes VLDL (TG rich)–> lipoprotein lipase break down TG into FFA–> used for energy–> remant (IDL)–> broken down by LPL again to LDL–> taken up by liver or recycled by HDLs
exam findings associated w/ severe hypertriglyceridemia
- Lipemia retinalis
- eruptive xanthomas (on weight baring areas-buttocks, shoulders, arms and legs but may occur all over the body)
- Lipemic serum (doesnt cause MI but does cause pancreatitis
how often should you be tested for dyslipidemia
- Adults 20 y/o and older should have a fasting lipid panel done at least every 5 years
- kids screen 9-11y/o and then at teenage yrs too unless FHX screen earilier
In those whose 10-year risk is less than 7.5% (5-7.5%) or when the decision is unclear, other factors may be used to enhance the treatment decision making including:
- Family History of Premature ASCVD
- LDL-C greater than 160 mg/dl
- hsCRP greater/equal 2 mg/dl (inflammation)
- Coronary Calcium Scoregreater/equal 300 Agatston units or greater/equal 75th percentile for age, sex, ethnicity
- ABI less than 0.9
“other” life-habit Cardiac risk factors
- Obesity (central/abdominal)
- Insulin Resistance (IFG, IGT)
- Sedentary Lifestyle (lean and unfit is also unhealthy)
- Atherogenic Diet
- Pyschosocial Factors
if statin therapy does not achieve anticipated LDL Reduction consider:
- Consider adherence issues
- Consider dose titration and/or combination therapy especially in high-risk individuals
what lab values should you obtain when checking lipids?
- complete lipoprotein profile after 8-12 hr fast (no chylomircons)
- Measure: Total Cholesterol, HDL, LDL** and Triglycerides
what is the physiological purpose of cholesterol
- used for synthesis and repair of cell membranes and organelles
- precursor of steroid hormones
moderate-intensity statin therapy effects and drug examples
-daily dose lowers LDL-C on avg by greater/equal 30-50%
Atorvastatin 10 (20) mg Rosuvastatin (5) 10 mg Simvastatin 20-40 mg Pravastatin 40 (80) mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg BID Pitavastatin 2-4 mg
major recommendations for statin therapy for ASCVD prevention
- heart healthy habits
- recalc. 10yr ASCVD risk every 4-6 yrs in individuals 40-75y w/o clinical ASCVD or diabetes and with LDL-C 70-189mg/dL